MMEA
SWTX

Main Management ETF Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Main Management ETF Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,360
Closed -$772K – 213
2024
Q4 		$772K Sell
21,360
-1,920
-8% -$67.1K 0.04% 100
2024
Q3 		$746K Buy
+23,280
New +$870K 0.04% 125

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Main Management ETF Advisors's SWTX Position: Q1 2025 in Review

Main Management ETF Advisors sold out of SpringWorks Therapeutics (SWTX) in Q1 2025, closing a stake of 21,360 shares — an estimated $772K sold.

Main Management ETF Advisors first reported a position in SWTX in Q3 2024 and held it in 2 quarters. The position peaked at $772K in Q4 2024. 306 funds tracked by Wall St. Rank hold SWTX as of Q1 2025.

  • Main Management ETF Advisors reported no remaining SpringWorks Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Main Management ETF Advisors sold 21,360 SpringWorks Therapeutics shares in Q1 2025, an estimated $772K.
  • Main Management ETF Advisors first reported a position in SpringWorks Therapeutics in Q3 2024 and held it in 2 quarters.
  • Main Management ETF Advisors's SpringWorks Therapeutics position peaked at $772K in Q4 2024.
  • 306 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2025.

Based on Main Management ETF Advisors's 13F filing for Q1 2025, filed 15 May 2025.